SEC Tracker
Get the app
DNTH · XBRL financial data

Dianthus Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (DNTH's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Revenueyear only1221*1000*———
Revenue from contracts with customers0*1221*1000*———
Research and development9*13182626*27263260*354946
General and administrative5*6677*79810*121414
Total operating expenses13*19243233*34354170*476260
Operating income (loss)(13)*(18)(22)(30)(32)*(33)(35)(40)(70)*(47)(61)(58)
Interest incomeyear only4421*2214*5611
Other income (expense)(0)*(0)(0)0(0)*(0)(0)(0)(0)*(0)(0)(0)
Income tax expense (benefit)year only———year only———year only———
Net income (loss)(11)*(14)(18)(25)(28)*(30)(32)(37)(64)*(41)(50)(47)
Earnings per share, basic USD per share—(0.54)(0.51)(0.74)(0.73)*(0.82)(0.88)(0.97)(1.43)*(0.85)(0.90)(0.81)
Earnings per share, diluted USD per share—(0.54)(0.51)(0.74)(0.73)*(0.82)(0.88)(0.97)(1.43)*(0.85)(0.90)(0.81)
Weighted average shares, basic millions of shares—26343439*36363845*485657
Weighted average shares, diluted millions of shares—26343439*36363845*485657

Balance sheet

CSV

Fiscal quarters (DNTH's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents13233031434231013565162811156
Short-term investments414747247252253244347353484776782
Marketable securities—————————287——
Accounts receivable001111050101
Prepaid and other current assets33345766571118
Total current assets1773813662872812712644144091,120898856
Property and equipment, net000000000001
Right-of-use asset110021111111
Total assets1793823693543743493265775311,2471,2131,276
Accounts payable3348585710565
Accrued liabilities7668138141619312621
Total current liabilities10910161817202431383429
Lease liability, non-current000011111111
Total liabilities111011162220233138464135
Accumulated deficit(89)(103)(121)(146)(174)(204)(236)(272)(337)(378)(428)(474)
Total stockholders' equity1693733583383523293035464931,2011,1721,241
Total liabilities and equity1793823693543743493265775311,2471,2131,276
Common shares outstanding (cover page) millions of shares292929303232324344555656

Cash flows

CSV

Fiscal quarters (DNTH's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)(11)*(14)(18)(25)(28)*(30)(32)(37)(64)*(41)(50)(47)
Stock-based compensation1*23*4*4*56*6*6*1112*13*
Net cash from operating activities(12)*(15)(15)*(21)*(27)*(28)(24)*(31)*(47)*(29)(49)*(50)*
Net cash from investing activities(8)*(6)1*(259)*(23)*1526*(201)*37*(134)(479)*(112)*
Proceeds from issuing common stockyear only00*0*39*00*0*0*00*0*
Net cash from financing activities(5)*218(2)*0*40*01*275*5*73910*107*
Net change in cash(25)*197(16)*(280)*(11)*(13)3*43*(5)*577(517)*(55)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Dianthus Therapeutics56not reported(50)*56.3M19.6 quarters 10-QSep 30, 2026
Stoke Therapeutics10711(63)*65.4M5.2 quarters 10-QSep 30, 2026
Trevi Therapeutics54not reported(17)*142.5M18.3 quarters 10-QJun 30, 2026
Amphastar Pharmaceuticals22418451*42.5M— 10-QJun 30, 2026
Anaptysbio13427*(27)*29.9M6.2 quarters 10-KTJun 30, 2026
Evolus4278(1.9)*66.2M7.7 quarters 10-QSep 30, 2026
Xencor601172.6*75.0M— 10-QSep 30, 2026
Savara42not reported(30)*205.5M5.8 quarters 10-QJun 30, 2026
Opko Health38465(36)*742.5M10.8 quarters 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.